Theralink Technologies Inc 's ROA from the first quarter of 2024 to the first quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Theralink Technologies Inc 's ROA in the first quarter of 2024?
Theralink Technologies Inc recorded a cumulative net loss of $-60 million during 12 months ending in the first quarter of 2024, resulting in a negative return on assets (ROA) of -3073.14%.

However, within the Healthcare sector 1175 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2023 from to 6007.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2023) I. Quarter	(Jun 30 2023) III. Quarter	(Mar 31 2023) II. Quarter	(Dec 31 2022) I. Quarter	(Sep 30 2022) IV. Quarter
Y / Y Total Assets Change	-73.77 %	-25.99 %	-10.67 %	33.48 %	43.28 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-60	-48	-54	-48	-13
Return On Assets (TTM)	-3073.14 %	-1994.99 %	-2130.49 %	-1820.23 %	-529.81 %
OBMP's Total Ranking	# 6007	#	# 5534	# 5663	# 6473
Total Assets (TTM) in million	1	2	2	3	3
Seq. Total Assets Change	-56.8 %	-29.77 %	-30.83 %	24.99 %	21.88 %
Seq. Net Income Change	-	-	-	-	-

OBMP's 5 Years Annual ROA >> Back to OBMP Management Effectiveness >> Compare OBMP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 580
Sector	# 1176
Overall	# 5861

Return On Assets Statistics
High	Average	Low
3228.9 %	-1061.72 %	-7236.95 %
(Dec 31 2018)		(Jun 30 2018)

Financial Statements
Theralink Technologies Inc 's Assets	$ 1 million	OBMP's Balance sheet
Theralink Technologies Inc 's Income	$ -19 million	Quarterly OBMP's Income Statement
OBMP's Income by Division		See OBMP's Income by Division

Annual Return On Assets	(Sep 30 2022) FY 2022	(Dec 31 2019) FY 2019	(Dec 31 2018) FY 2018	(Dec 31 2017) FY 2017	(Dec 31 2016) FY 2016
Y / Y Total Assets Change	2660.16 %	-58.44 %	733.77 %	-52.59 %	-92.11 %
Total Assets in million	3	0	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-13	-9	6	-21	-2
Annual Return On Assets	-493.36 %	-9985.6 %	2854.69 %	-75482.55 %	-3512.84 %

OBMP's 5 Years Annual ROA >> Back to OBMP Management Effectiveness >> Compare OBMP ROA to its Competitors

More Return On Assets Ratios
OBMP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
OBMP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for OBMP's Competitors
Subscribers only: Roa for Theralink Technologies Inc 's Suppliers
Subscribers only: Return On Assets for OBMP's Customers

You may also want to know
OBMP's Roi	OBMP's Inventory Turnover Ratio	OBMP's Growth Rates	OBMP's Dividend Comparisons
	OBMP's Profitability Ratios	OBMP's Asset Turnover Ratio	OBMP's Dividend Growth
OBMP's Roe	OBMP's Valuation Ratios	OBMP's Financial Strength Ratios	OBMP's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2023, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.